Literature DB >> 15841616

Is the use of early nasal CPAP associated with lower rates of chronic lung disease and retinopathy of prematurity? Nine years of experience with the Vermont Oxford Neonatal Network.

Lieselotte Kirchner1, Manfred Weninger, Lukas Unterasinger, Robert Birnbacher, Michael Hayde, Reinhard Krepler, Arnold Pollak.   

Abstract

OBJECTIVE: The neonatal regional tertiary care center of the University of Vienna (VC) has been a member of the Vermont Oxford Neonatal Network (VONN) since 1994. During the period 1994--2002, important differences between the VC and the VONN in both pre- and postnatal management and in late morbidities such as chronic lung disease (CLD) and severe retinopathy of prematurity (ROP) were observed. We hypothesize that stabilization of very-low-birth-weight (VLBW) infants on nasal continuous positive airway pressure (NCPAP) immediately after birth, combined with a restrictive use of artificial ventilation, might be responsible for lower rates of CLD and ROP. PATIENTS AND METHODS: Obstetric and neonatal data for all 1299 VLBW infants (401-1500 g) from the VC were compared with corresponding data for the 201,167 VLBW infants from the VONN for the period 1994--2002 with regard to respiratory management and patient outcome. Morbidity criteria were in accordance with VONN definitions.
RESULTS: The percentage range for treatment and morbidity criteria for the VC and VONN are related to differences among various years within the observation period. Infants were stabilized at birth on NCPAP in 45-86% of cases in the VC vs. 37-63% in the VONN, the rate of mechanical ventilation was 40-59% vs. 66-74%, and use of surfactant was 31-50% vs. 55-64%. CLD was diagnosed in 14-32% of cases in the VC vs. 27-39% in the VONN, discharge on supplemental oxygen took place in 2-4% vs. 12-17% of cases and ROP (stages III and IV) was found in 1-10% vs. 8-12%.
CONCLUSION: The association of lower rates of CLD and ROP in the VC compared to the VONN might be related to differences in early respiratory management of VLBW infants at high risk of development of respiratory distress syndrome. This needs to be confirmed in a large multicenter trial.

Entities:  

Mesh:

Year:  2005        PMID: 15841616     DOI: 10.1515/JPM.2005.010

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  6 in total

Review 1.  Neonatal nasal intermittent positive pressure ventilation: what do we know in 2007?

Authors:  Louise S Owen; Colin J Morley; Peter G Davis
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-09       Impact factor: 5.747

2.  Nasal continuous positive airway pressure and outcomes in preterm infants: A retrospective analysis.

Authors:  Gustavo Pelligra; Mohamed A Abdellatif; Shoo K Lee
Journal:  Paediatr Child Health       Date:  2008-02       Impact factor: 2.253

3.  Resuscitation intensity at birth is associated with changes in brain metabolic development in preterm neonates.

Authors:  Emma G Duerden; Meisan Brown-Lum; Vann Chau; Kenneth J Poskitt; Ruth E Grunau; Anne Synnes; Steven P Miller
Journal:  Neuroradiology       Date:  2013-08-07       Impact factor: 2.804

4.  Long use of continuous positive airway pressure protects against the development of treatment-requiring retinopathy of prematurity.

Authors:  Shutaro Suga; Yuki Kyono; Takumi Kido; Ruka Nakasone; Shinya Abe; Mariko Ashina; Kandai Nozu; Kazumichi Fujioka
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.379

5.  Comparison of neonatal intensive care: Trento area versus Vermont Oxford Network.

Authors:  Giuseppe De Nisi; Mariarosaria Berti; Riccardo Malossi; Fabio Pederzini; Anna Pedrotti; Alberta Valente
Journal:  Ital J Pediatr       Date:  2009-03-14       Impact factor: 2.638

6.  Application of continuous positive airway pressure in the delivery room: a multicenter randomized clinical trial.

Authors:  W A Gonçalves-Ferri; F E Martinez; J P S Caldas; S T M Marba; S Fekete; L Rugolo; C Tanuri; C Leone; G A Sancho; M F B Almeida; R Guinsburg
Journal:  Braz J Med Biol Res       Date:  2014-01-29       Impact factor: 2.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.